Optimizing mercaptopurine therapy in indian pediatric ALL: The role of TPMT and NUDT15 genetic polymorphisms

Jayalakshmi Venugopal; Shalini Sivadasan; Rajasekaran Aiyalu

doi:10.1016/j.ctarc.2026.101173

January 1, 2026Cancer Treatment and Research CommunicationsOpen Access

Optimizing mercaptopurine therapy in indian pediatric ALL: The role of TPMT and NUDT15 genetic polymorphisms

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to analyze how NUDT15 and TPMT genetic variations influence mercaptopurine dosage in Indian children with ALL.
Genotyping of TPMT and NUDT15 genetic polymorphisms was performed.
Evaluation of prevalence rates of genetic variations among the study population.
Assessment of implications for dosing adjustments based on genetic findings.
NUDT15 variations were found to be more common than TPMT variations among Indian patients.
Genotyping results may lead to more accurate mercaptopurine dosing, reducing the risk of infections.

Implication

Evaluation shows NUDT15 variants affect mercaptopurine dosage in pediatric ALL, suggesting tailored treatments.

Abstract

This evaluation indicates that NUDT15 variations are more prevalent than TPMT among Indian patients. Consequently, the genotyping of TPMT and NUDT15 before MP treatment may assist in determining the appropriate dosage of MP to prevent life-threatening infections.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Venugopal et al. (2026) studied this question.

synapsesocial.com/papers/69b64c67b42794e3e660db12 https://doi.org/10.1016/j.ctarc.2026.101173

View Full Paper

Ask AI

Bookmark

Share

Optimizing mercaptopurine therapy in indian pediatric ALL: The role of TPMT and NUDT15 genetic polymorphisms

Key Points

Implication

Abstract

Discussion

Cite This Study

Optimizing mercaptopurine therapy in indian pediatric ALL: The role of TPMT and NUDT15 genetic polymorphisms

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading